Glasgow Early Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19: a structured summary of a study protocol for a randomised controlled trial

Catherine R. Hanna, Kevin G. Blyth, Glenn Burley, Samantha Carmichael, Carol Evans, Samantha Hinsley, Ibrahim Khadra, Saye Khoo, Liz-Anne Lewsley, Robert R. Jones, Raman Sharma, Andrea Taladriz-Sender, Emma C. Thomson, Janet T. Scott

Research output: Contribution to journalLetterpeer-review

1 Downloads (Pure)


The GETAFIX trial will test the hypothesis that favipiravir is a more effective treatment for COVID-19 infection in patients who have early stage disease, compared to current standard of care. This study will also provide an important opportunity to investigate the safety and tolerability of favipiravir, the pharmacokinetic and pharmacodynamic profile of this drug and mechanisms of resistance in the context of COVID-19 infection, as well as the effect of favipiravir on hospitalisation duration and the post COVID-19 health and psycho-social wellbeing of patients recruited to the study.
Original languageEnglish
Article number935
Number of pages3
Publication statusPublished - 19 Nov 2020


  • GETAFIX trial
  • Covid-19
  • patient study

Cite this